←
Michael Mindrum, MD23,924 posts
Michael Mindrum, MD avatar

Michael Mindrum, MD

@MichaelMindrum

Internal Medicine & obesity specialist. Born in 🇺🇸, 🇨🇦 is home.

◷ Joined January 2018▧ 1,276 Photos and videos
Beverly G. Tchang, MD avatar
⟳ Michael Mindrum, MD retweeted
Beverly G. Tchang, MD@BevTchangMD·Nov 17

I am absolutely honored and humbled to receive the 2026 TOS Clinician of the Year Award. I truly believe every clinician could be deserving of this honor. As clinicians, patient care is core to our values, motivations, and actions, which is why we all go above and beyond our medical training to do more than just our "job." - Advocacy: How many times have you filled out prior authorizations, appeals, and done peer-to-peers? - Education: How many times have you discussed information from the Internet/AI and helped the patient understand whether or not it was applicable to them? Information is not education until you bring it back to the patient. - Research: How many times has a patient asked you about a side effect or effect, not known to be related to your intervention? Research starts and ends with patient experiences. I am grateful for The @ObesitySociety that has served as my second professional home and appreciate the gracious words from Yael Mauer, MD, MPH, FACP, DABOM, DACD and @cabandup Peminda Cabandugama MD DABOM FTOS . Thank you to everyone who has supported me throughout my career thus far including @OMFellowships and @ABOMcert @Ro , and in particular, ⭐️Alpana Shukla, MD, MRCP(UK), FTOS @alpanashuklamd who has always served as my compass--both professional and personally--and ⭐️@ljaronne Louis Aronne who had once encouraged me to "get in trouble" and still stands by me today when I do. I could not have a better work-family than I do at @WeillCornell Medicine Comprehensive Weight Control Center. #obesity #medicine #obesityweek2026 #OW2026

Max Marchione avatar
⟳ Michael Mindrum, MD retweeted
Max Marchione@maxmarchione·Nov 15

24 weight-loss drugs, ranked by how much weight people lost compared with placebo. Retatrutide is #1 at 22%.

Post attachment
Magnesium Girl - yin solutions for a yang world avatar
⟳ Michael Mindrum, MD retweeted
Magnesium Girl - yin solutions for a yang world@LocalRachel·Nov 14

Just a reminder the Calories Model on body mass is flawed. This study was only on male twins too - female physiology is far more complex and environmentally dictated.

1. If you & your friend (same size, age, weight) ate the same 1,000-calorie surplus every day for 3 months, will you gain the same amount of weight? A landmark experiment on identical twins helps us answer this question and that our 🧬 direct the body's response to overeating 🧵

Post attachment
Michael Mindrum, MD avatar
Michael Mindrum, MD@MichaelMindrum·Nov 12

Listened to Jensen Huang's long form podcast w/ Lex Friedman a couple weeks ago. He came across as supremely confident in his leadership and visionary talent. He didn't see anything that could get in the way of Nvidia's growth or his leadership in the company. He discussed how quickly he transmitted information to others in the company - anything I know, they know, immediatetly. I guess he didn't share everything though.

Michael Mindrum, MD avatar
Michael Mindrum, MD@MichaelMindrum·Nov 12

“I think that would be amazing and I think it’s not likely” 🤣

I think that would be amazing and I think it’s not likely. The map of biology is still largely a blank page and randomized human proof is the long pole in the tent. I am excited about the use of AI in our sector but progress will likely be steady and incremental.

Michael Mindrum, MD avatar
Michael Mindrum, MD@MichaelMindrum·Nov 11

Yes! It’s beautiful to see knowledge 😍

Sleeping better, walking more and eating real food are wins even in a week the scale doesn't move. Tying them only to the number is how people quit habits that were working.

Beverly G. Tchang, MD avatar
⟳ Michael Mindrum, MD retweeted
Beverly G. Tchang, MD@BevTchangMD·Nov 11

The data exploring #GLP1 and #cancer continues to expand: jamanetwork.com/journals/jam… This retrospective observational study of electronic health records looked at electronic health records for about 360,000 adults with type 2 #diabetes at UT Southwestern (2010–2025) who had no prior obesity-related cancer. They compared people starting a GLP-1 drug vs. those who started metformin, insulin, an SGLT2 inhibitor, a DPP-4 inhibitor, or a sulfonylurea — five separate head-to-head comparisons, matched with propensity weighting. Then they split everyone by how severe their diabetes was at baseline. Their findings: - At 3 years, GLP-1 starters had lower obesity-related cancer risk than insulin starters (1.25 percentage points lower; HR 0.62) and sulfonylurea starters (1.14 points lower; HR 0.67). - No meaningful difference versus metformin, SGLT2 inhibitors, or DPP-4 inhibitors. - At 5 years, the gap vs insulin held (−1.67 points; HR 0.61) and vs sulfonylureas (HR 0.75). - The advantage was clearest in people with milder diabetes. In the most severe group, the 3-year comparison actually favored SGLT2 inhibitors over GLP-1s. In oncology, no one is surprised that GLP1s were better than insulin starters since insulin is an anabolic hormone--ie, it stimulates growth. A nice plain language summary here: medicalxpress.com/news/2026-… HT: Jaime Almandoz, MD, MBA, FTOS!

Michael Mindrum, MD avatar
Michael Mindrum, MD@MichaelMindrum·Nov 11

I spend my day helping people divorce the concepts of “healthy behaviour” and the “number on the scale.” Diet culture marries these two ideas. Diet culture has created multi-billion dollar weight loss programs that has taken advantage of our misunderstanding and led to misplaced blame and shame. Diet culture needs to die. The end goal of behaviour change is to see healthy behaviours in our life…. and *body weight* is not a behaviour.

This is demonstrably false. In 40 years, there has not been a single lifestyle intervention that, in trials, worked for long-term weight loss. GLP-1 users lose weight *and* improve their diet. You guys had nearly a half-century to come up with something, and you didn't.

Michael Mindrum, MD avatar
Michael Mindrum, MD@MichaelMindrum·Nov 11

A number of patients I know who would have benefited from timely access to bariatric surgery in Nova Scotia have died because our health system ignored them. In my view, this is discrimination and a human rights issue. It is a tragedy that very physicians or healthcare leaders recognize or acknowledge.

Daniel J Drucker avatar
⟳ Michael Mindrum, MD retweeted
Daniel J Drucker@DanielJDrucker·Nov 11

Rare GLP1R variants (about 1:500) attenuate weight loss with semaglutide but not tirzepatide, whereas rare LOF GIPR variants have little effect on drug responses lnkd.in/p/g_RD5nDP

Michael Mindrum, MD avatar
Michael Mindrum, MD@MichaelMindrum·Nov 11

Nice review by Dr. Matthias Blüher on the pathophysiology of obesity and its pharmacotherapy.

A new #ScienceReview highlights progress in the development of obesity management medications (OMMs), including GLP-1 receptor agonists, as well as key limitations associated with these medications, such as gastrointestinal side effects, variable treatment responses, loss of muscle mass, and weight regain after stopping treatment. Learn more: scim.ag/4eDUQpN

Post attachment
Crémieux avatar
⟳ Michael Mindrum, MD retweeted
Crémieux@cremieuxrecueil·Nov 11

The FDA has fallen into an amusing trap. GLP-1RAs don't cause this. But, some of the conditions it treats do. Result? 'Warning!'

CNN@CNNNov 9

The US health regulator on Monday informed patients and healthcare providers of a potential increased ​risk of a serious eye condition associated with the use of ‌GLP-1 drugs for weight loss and diabetes. cnn.com/2026/11/09/health/gl…

Scott Isaacs avatar
⟳ Michael Mindrum, MD retweeted
Scott Isaacs@scottisaacsmd·Nov 1

In adults with obesity, a very low carbohydrate diet reduced intermuscular fat by 24.4% vs 1.0% with a low fat diet over 8 weeks. Greater reductions were associated with improved strength and function. #VLCD onlinelibrary.wiley.com/doi/…

Post attachment
Michael Albert, MD avatar
⟳ Michael Mindrum, MD retweeted
Michael Albert, MD@MichaelAlbertMD·Nov 10

What happens when you spend your life being told to lose weight, only to be told you’re “too healthy” for treatment? I’m pleased to welcome Dr. Michael Mindrum as a guest author in Substance Over Noise. His essay explores one of obesity medicine’s hardest questions: when someone has “metabolically healthy obesity,” what are we treating, and how far should we go? Through a patient’s story, he examines prevention, the limits of our evidence, and the difference between pursuing better health and chasing a smaller body. Read his piece here: [Metabolically Healthy Obesity: What Are We Treating?](read.michaelalbertmd.com/p/m…)